Clinical trialsCompany release

Moleculin completes dosing of 90 patients in Part A of pivotal AML trial MIRACLE

🇺🇸 Moleculin Biotech, Inc. (MBRX) · Mon 16 Nov 2026

Part A data for Annamycin plus cytarabine in relapsed or refractory AML are expected in the first quarter of 2027 and will guide dose selection for Part B.

Moleculin Biotech has said that all 90 patients enrolled in Part A of its Phase 2/3 MIRACLE trial have completed treatment. The study is testing Annamycin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukaemia (AML). The update came with the company's third-quarter 2026 results, published on 16 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Moleculin Biotech, Inc. ↗

Article written by VigiEye from the official source (Moleculin Biotech, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →